NCT04844658

Covid-19, Hospitalized, PatIents, Nasafytol

Completed NA Last updated 13 October 2022

What this trial tests

NA trial testing NASAFYTOL® in Coronavirus Infection in 51 participants. Completed in 31 March 2022.

Timeline

17 February 2021

Primary endpoint
29 October 2021

31 March 2022

Quick facts

Lead sponsor	Tilman S.A.
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	supportive care
Enrollment	51
Start date	17 February 2021
Primary completion	29 October 2021
Estimated completion	31 March 2022
Sites	1 location across Belgium

Drugs / interventions tested

• NASAFYTOL®
• FULTIUM® -D3 800
• Strandard of care treatment — full drug profile →

Conditions studied

• Coronavirus Infection — all drugs for Coronavirus Infection →

Sponsor

Tilman S.A. — full company profile →

Who can join

18 and older, any sex, with Coronavirus Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to evaluate the effect and safety of NASAFYTOL® on COVID-19 positive hospitalized patients as a supportive supplementation to standard-of-care in improving clinical parameters safely during hospital admission (maximum 14 days).

The study is a standard-of-care comparative, open, parallel two-arms and randomized trial in 50 adult patients positive to COVID-19 infection and hospitalized. It will be monocentric but may be extended to several investigation sites (multicentric) depending on the evolution of the epidemic within the hospitals.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Promising Antiviral Activities of Natural Flavonoids against SARS-CoV-2 Targets: Systematic Review.
   Kaul R, Paul P, Kumar S, Büsselberg D, et al · · 2021 · cited 61× · PMID 34681727 · DOI 10.3390/ijms222011069
2. The Therapeutic and Prophylactic Potential of Quercetin against COVID-19: An Outlook on the Clinical Studies, Inventive Compositions, and Patent Literature.
   Imran M, Thabet HK, Alaqel SI, Alzahrani AR, et al · · 2022 · cited 45× · PMID 35624740 · DOI 10.3390/antiox11050876
3. Reconnoitering the Therapeutic Role of Curcumin in Disease Prevention and Treatment: Lessons Learnt and Future Directions.
   Sivani BM, Azzeh M, Patnaik R, Pantea Stoian A, et al · · 2022 · cited 26× · PMID 35888763 · DOI 10.3390/metabo12070639
4. Molecular Mechanisms of Possible Action of Phenolic Compounds in COVID-19 Protection and Prevention.
   Gligorijevic N, Radomirovic M, Nedic O, Stojadinovic M, et al · · 2021 · cited 14× · PMID 34830267 · DOI 10.3390/ijms222212385
5. Pharmaceutical Prospects of Curcuminoids for the Remedy of COVID-19: Truth or Myth.
   Fu YS, Ho WY, Kang N, Tsai MJ, et al · · 2022 · cited 13× · PMID 35496320 · DOI 10.3389/fphar.2022.863082
6. Stand Up to Stand Out: Natural Dietary Polyphenols Curcumin, Resveratrol, and Gossypol as Potential Therapeutic Candidates against Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
   Wang Z, Song XQ, Xu W, Lei S, et al · · 2023 · cited 12× · PMID 37764669 · DOI 10.3390/nu15183885
7. A critical evaluation of risk to reward ratio of quercetin supplementation for COVID-19 and associated comorbid conditions.
   Pawar A, Russo M, Rani I, Rani I, et al · · 2022 · cited 12× · PMID 35393674 · DOI 10.1002/ptr.7461
8. Therapeutic implications of quercetin and its derived-products in COVID-19 protection and prophylactic.
   Ho WY, Shen ZH, Chen Y, Chen TH, et al · · 2024 · cited 10× · PMID 38765079 · DOI 10.1016/j.heliyon.2024.e30080